Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB receptors.

Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
Author Information
  1. Xiao Zhu: Otago Pharmacometrics Group, School of Pharmacy, University of Otago, Dunedin, New Zealand. ORCID
  2. David B Finlay: Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. ORCID
  3. Michelle Glass: Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. ORCID
  4. Stephen B Duffull: Otago Pharmacometrics Group, School of Pharmacy, University of Otago, Dunedin, New Zealand. ORCID

Abstract

BACKGROUND AND PURPOSE: Receptor internalisation is by nature kinetic. Application of a standard equilibrium dose response model to describe the properties of a ligand inducing internalisation, while commonly used, are therefore problematic. Here, we propose two quantitative approaches to address this issue-(a) a model-free method and (b) a kinetic modelling approach-and systematically evaluate the performance of these methods against traditional equilibrium methods to characterise the internalisation profiles of cannabinoid CB receptor agonists.
EXPERIMENTAL APPROACH: Kinetic internalisation assays were conducted using a concentration series of six CB receptor ligands. Internalisation rate analysis and snapshot equilibrium analysis were performed. A model-free method was developed based on the mean residence time of internalisation. A kinetic internalisation model was developed under the quasi-steady state assumption.
KEY RESULTS: Rates of receptor internalisation depended on both agonist and concentration. Agonist potencies from snapshot equilibrium analysis increased with stimulation time, and there was no single time point at which internalisation profiles could infer agonist properties in a comparative manner. The model-free method yielded a time-invariant measure of potency/efficacy for internalisation. The kinetic model adequately described the internalisation of CB receptors over time and provided robust estimates of both potency and efficacy.
CONCLUSION AND IMPLICATIONS: Applying equilibrium analysis to a non-equilibrium pathway cannot provide a reliable estimate of agonist potency. Both the model-free and kinetic modelling approaches characterised the internalisation profiles of CB receptor agonists. The kinetic model provides additional advantages as a method to capture changes in receptor number during other functional assays.

References

  1. CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122 [PMID: 27069774]
  2. Clin Pharmacokinet. 2012 Apr 1;51(4):247-60 [PMID: 22420579]
  3. Br J Pharmacol. 2019 Jul;176(14):2593-2607 [PMID: 30945265]
  4. Br J Pharmacol. 2018 Apr;175(7):987-993 [PMID: 29520785]
  5. Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106 [PMID: 29149325]
  6. Front Endocrinol (Lausanne). 2015 Aug 27;6:130 [PMID: 26379624]
  7. Best Pract Res Clin Endocrinol Metab. 2018 Apr;32(2):83-91 [PMID: 29678288]
  8. J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):5-16 [PMID: 22101760]
  9. Pharmacol Rev. 2002 Jun;54(2):161-202 [PMID: 12037135]
  10. Br J Pharmacol. 2017 Dec;174 Suppl 1:S17-S129 [PMID: 29055040]
  11. J Biol Chem. 2004 Aug 20;279(34):36013-21 [PMID: 15210689]
  12. Mol Pharmacol. 2014 Mar;85(3):492-509 [PMID: 24366668]
  13. Pharmacol Rev. 2010 Dec;62(4):588-631 [PMID: 21079038]
  14. J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):507-32 [PMID: 11999290]
  15. PeerJ. 2016 Mar 21;4:e1835 [PMID: 27018161]
  16. Curr Chem Genom Transl Med. 2013 Jul 26;7:9-15 [PMID: 24396730]
  17. Clin Pharmacokinet. 2012 Jun 1;51(6):e1-18 [PMID: 22550964]
  18. AAPS J. 2019 Aug 5;21(5):97 [PMID: 31385119]
  19. Pharm Res. 2005 Oct;22(10):1589-96 [PMID: 16180117]
  20. ACS Chem Neurosci. 2012 Mar 21;3(3):193-203 [PMID: 22860188]
  21. Assay Drug Dev Technol. 2003 Apr;1(2):327-38 [PMID: 15090198]
  22. Life Sci. 2003 Dec 5;74(2-3):217-24 [PMID: 14607249]
  23. J Pharmacol Toxicol Methods. 2015 Jan-Feb;71:42-5 [PMID: 25479109]
  24. J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):573-91 [PMID: 19005743]
  25. Annu Rev Pharmacol Toxicol. 2008;48:537-68 [PMID: 18184106]
  26. Proc R Soc Lond B Biol Sci. 1983 Dec 22;220(1219):141-62 [PMID: 6141562]
  27. J Theor Biol. 2018 Jun 7;446:168-204 [PMID: 29486201]
  28. Nat Rev Drug Discov. 2018 Apr;17(4):243-260 [PMID: 29302067]
  29. Br J Pharmacol. 2013 Oct;170(4):893-907 [PMID: 23937487]
  30. Front Endocrinol (Lausanne). 2015 Nov 09;6:167 [PMID: 26617570]
  31. J Pharmacol Exp Ther. 2007 Jan;320(1):1-13 [PMID: 16803859]
  32. Mol Pharmacol. 2001 Nov;60(5):1049-56 [PMID: 11641433]
  33. Biochem Pharmacol. 2010 Oct 1;80(7):1050-62 [PMID: 20599795]
  34. Clin Exp Pharmacol Physiol. 2008 Nov;35(11):1377-82 [PMID: 18565191]
  35. Br J Pharmacol. 2017 Aug;174(15):2545-2562 [PMID: 28516479]
  36. Nat Commun. 2016 Feb 24;7:10842 [PMID: 26905976]
  37. J Pharmacokinet Biopharm. 1998 Apr;26(2):207-46 [PMID: 9795882]

MeSH Term

Cannabinoid Receptor Agonists
Cells, Cultured
Humans
Kinetics
Models, Biological
Receptor, Cannabinoid, CB1

Chemicals

Cannabinoid Receptor Agonists
Receptor, Cannabinoid, CB1

Word Cloud

Created with Highcharts 10.0.0internalisationkineticequilibriumCBreceptormodelmodel-freemethodanalysistimeapproachesmodellingprofilesagonistANDpropertiesmethodscannabinoidagonistsassaysconcentrationInternalisationsnapshotdevelopedreceptorspotencynon-equilibriumpathwayBACKGROUNDPURPOSE:ReceptornatureApplicationstandarddoseresponsedescribeligandinducingcommonlyusedthereforeproblematicproposetwoquantitativeaddressissue-bapproach-andsystematicallyevaluateperformancetraditionalcharacteriseEXPERIMENTALAPPROACH:Kineticconductedusingseriessixligandsrateperformedbasedmeanresidencequasi-steadystateassumptionKEYRESULTS:RatesdependedAgonistpotenciesincreasedstimulationsinglepointinfercomparativemanneryieldedtime-invariantmeasurepotency/efficacyadequatelydescribedprovidedrobustestimatesefficacyCONCLUSIONIMPLICATIONS:ApplyingprovidereliableestimatecharacterisedprovidesadditionaladvantagescapturechangesnumberfunctionalModel-freecharacterisingpharmacologicalactivity:

Similar Articles

Cited By (11)